Image Place holder

Michael Mann, PhD

Program: Molecular Oncology

View Lab Page


Dr. Mann’s research programs use innovative genetic and genomic approaches to discover the mutational events that initiate, maintain, and contribute to acquired therapeutic resistance during the evolution of melanoma and non-melanoma skin cancers   .


    • Molecular Oncology
    • Cutaneous Oncology
    • Cancer Biology and Evolution Program
    • Melanoma Research Center of Excellence
    • Cancer Biology and Evolution Program

Education & Training


  • Case Western Reserve University - PhD - Genetics
  • California State Polytechnic University - MS - Biological Sciences


  • National Cancer Institute, Fellow - Mouse Cancer Genetics
  • Institute of Molecular & Cell Biology, Fellow - Mammalian Genetics

Cancer gene discovery continues to drive cancer research with the promise of identifying new diagnostic markers and targeted therapeutics by defining novel genetic events that initiate, promote or sustain tumorigenesis. The overarching goal of my lab and research programs is to integrate genetic and genomic approaches to investigate cancer driver gene function(s) during the initiation and progression of skin cancer and to understand melanocyte and keratinocyte transformation at a systems level. Applying this information in the context of human cancer will advance skin cancer research and provide the infrastructure to formulate fundamental questions in other areas of human cancer science. To obtain a deep systems-level understanding of cutaneous cancer genomics, our work uses genetic and genomic information from unique mouse models we have developed in combination with both publicly available human cancer mutation data, and the invaluable mutation and clinical datasets and specimens available to Moffitt Cancer Center investigators. The long-term goal of my lab is to use these integrated data to design a new generation of pre-clinical mouse models for candidate cancer gene validation and to probe in vivo drug resistance mechanisms and therapeutic target gene/pathway selection with demonstrated biological importance and translational application.


  • Muradova E, Patel N, Sell B, Bittencourt BB, Ojeda SS, Adelmann CH, Cen L, Cheng CH, Shen J, Davis CM, Ehli EA, Newberg JY, Cherpelis B, Black MA, Mann MB, Mitragotri S, Tsai KY. Noninvasive Assessment of Epidermal Genomic Markers of UV Exposure in Skin. J Invest Dermatol. 2021 Jan.141(1):124-131.e2. Pubmedid: 32553564. Pmcid: PMC7736225.
  • Aiderus A, Contreras-Sandoval AM, Meshey AL, Newberg JY, Ward JM, Swing DA, Copeland NG, Jenkins NA, Mann KM, Mann MB. Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33435458. Pmcid: PMC7827284.
  • Aiderus A, Newberg JY, Guzman-Rojas L, Contreras-Sandoval AM, Meshey AL, Jones DJ, Amaya-Manzanares F, Rangel R, Ward JM, Lee SC, Ban KH, Rogers K, Rogers SM, Selvanesan L, McNoe LA, Copeland NG, Jenkins NA, Tsai KY, Black MA, Mann KM, Mann MB. Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression. PLoS Genet. 2021 Aug.17(8):e1009094. Pubmedid: 34398873. Pmcid: PMC8389471.
  • Newberg JY, Black MA, Jenkins NA, Copeland NG, Mann KM, Mann MB. SB Driver Analysis: a Sleeping Beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors. Nucleic Acids Res. 2018 Sep.46(16):e94. Pubmedid: 29846651. Pmcid: PMC6144815.
  • Newberg JY, Mann KM, Mann MB, Jenkins NA, Copeland NG. SBCDDB: Sleeping Beauty Cancer Driver Database for gene discovery in mouse models of human cancers. Nucleic Acids Res. 2018 Jan.46(D1):D1011-D1017. Pubmedid: 29059366. Pmcid: PMC5753260.
  • Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 Aug.198(2):281-288. Pubmedid: 28268170.
  • Mann KM, Newberg JY, Black MA, Jones DJ, Amaya-Manzanares F, Guzman-Rojas L, Kodama T, Ward JM, Rust AG, van der Weyden L, Yew CC, Waters JL, Leung ML, Rogers K, Rogers SM, McNoe LA, Selvanesan L, Navin N, Jenkins NA, Copeland NG, Mann MB. Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq. Nat Biotechnol. 2016 Sep.34(9):962-972. Pubmedid: 27479497. Pmcid: PMC6124494.
  • Rangel R, Lee SC, Hon-Kim Ban K, Guzman-Rojas L, Mann MB, Newberg JY, Kodama T, McNoe LA, Selvanesan L, Ward JM, Rust AG, Chin KY, Black MA, Jenkins NA, Copeland NG. Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. Proc Natl Acad Sci U S A. 2016 Nov.113(48):E7749-E7758. Pubmedid: 27849608. Pmcid: PMC5137755.
  • Mann MB, Black MA, Jones DJ, Ward JM, Yew CC, Newberg JY, Dupuy AJ, Rust AG, Bosenberg MW, McMahon M, Print CG, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma. Nat Genetics. 2015 May.47(5):486-495. Pubmedid: 25848750. Pmcid: PMC4844184.
  • Goh AM, Xue Y, Leushacke M, Li L, Wong JS, Chiam PC, Rahmat SA, Mann MB, Mann KM, Barker N, Lozano G, Terzian T, Lane DP. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 2015 Jul.6(20):17968-17980. Pubmedid: 26255629. Pmcid: PMC4627229.
  • Takeda H, Wei Z, Koso H, Rust AG, Yew CC, Mann MB, Ward JM, Adams DJ, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genetics. 2015 Feb.47(2):142-150. Pubmedid: 25559195.
  • Mann KM, Jenkins NA, Copeland NG, Mann MB. Transposon insertional mutagenesis models of cancer. Cold Spring Harb Protoc. 2014 Mar.2014(3):235-247. Pubmedid: 24591685.
  • Trevarton AJ, Mann MB, Knapp C, Araki H, Wren JD, Stones-Havas S, Black MA, Print CG. MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways. Front Oncol. 2013.3:184. Pubmedid: 23875173. Pmcid: PMC3712543.
  • Goh AM, Lim CY, Chiam PC, Li L, Mann MB, Mann KM, Menendez S, Lane DP. Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proc Natl Acad Sci U S A. 2012 Jan.109(5):1685-1690. Pubmedid: 22307631. Pmcid: PMC3277193.
  • Mann MB, Kaldis P. Cell cycle transitions and Cdk inhibition in melanoma therapy: cyclin' through the options. Cell Cycle. 2011 May.10(9):1349. Pubmedid: 21464616.
  • Mann MB, Hodges CA, Barnes E, Vogel H, Hassold TJ, Luo G. Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. Hum Mol Genet. 2005 Mar.14(6):813-825. Pubmedid: 15703196.
  • Mann MB, Wu S, Rostamkhani M, Tourtellotte W, MacMurray JP, Comings DE. Association between the phenylethanolamine N-methyltransferase gene and multiple sclerosis. J Neuroimmunol. 2002 Mar.124(1-2):101-105. Pubmedid: 11958827.
  • Mann MB, Wu S, Rostamkhani M, Tourtellotte W, MacMurray J, Comings DE. Phenylethanolamine N-methyltransferase (PNMT) gene and early-onset Alzheimer disease. Am J Med Genet. 2001 May.105(4):312-316. Pubmedid: 11378842.
  • Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Blake H, Mann MB, Dietz G, Saucier G, MacMurray JP. A multivariate analysis of 59 candidate genes in personality traits: the temperament and character inventory. Clin Genet. 2000 Nov.58(5):375-385. Pubmedid: 11140838.


  • Title: Anti-tumor Potential of Temperature-Sensitive p53 Mutants
    Sponsor: Nat Institutes of Health
    PI (Contact): Chen, J., PI (MPI): Mann, M.